Stay updated on ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial
Sign up to get notified when there's something new on the ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial page.

Latest updates to the ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial page
- Check2 days agoChange DetectedThe page now displays a recruitment status indicating no enrollment and adds guidance sections to help readers understand and join the study, while the Intervention/Treatment heading was reformatted from the previous label.SummaryDifference0.4%

- Check9 days agoChange DetectedThe revision tag on the page has been updated from Revision: v3.5.4 to Revision: v3.5.5, indicating a minor update to the page. This reflects an internal content/structure update and does not alter the listed study details.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision was updated from v3.5.3 to v3.5.4, signaling a new build of the page template; this reflects a backend release rather than a change to study information.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page footer revision label was updated from **v3.5.2** to **v3.5.3**, reflecting a site/version change rather than a modification to the clinical trial information.SummaryDifference0.0%

- Check59 days agoChange DetectedA minor software revision was applied, updating the page revision from v3.5.0 to v3.5.2. This change does not affect the study data, eligibility criteria, or core content on the page.SummaryDifference0.0%

- Check66 days agoChange DetectedPrimary Completion Date updated to 2026-12-23 and a new Last Update entry on 2026-04-07 were added. Several older date entries (e.g., 2026-02xx and 2026-04-23) were removed.SummaryDifference0.2%

Stay in the know with updates to ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADP-A2M4CD8 with Checkpoint Inhibitors in MAGE-A4+ Tumors Clinical Trial page.